MacroGenics Inc. Common Stock (MGNX)

FairStock Score: 46/100 — MIXED

Key Financials

Strengths

• Generates $12 million in annual free cash flow (5.7% yield on market cap)
• Revenue growth of 132.5% demonstrates strong top-line momentum

Concerns

• Currently unprofitable—sustained losses could lead to dilutive capital raises or balance sheet deterioration
• Weak Piotroski F-Score of 2/9 suggests deteriorating financial quality across multiple dimensions
• Altman Z-Score of -5.3 places it in the financial distress zone—elevated bankruptcy risk

AI Analysis

MacroGenics Inc. Common Stock is a micro-cap healthcare company valued at $206 million. Revenue stands at $157 million, though the company is currently unprofitable. From a quality standpoint, MacroGenics shows weak Piotroski F-Score of 2/9 signaling deteriorating fundamentals and distressed Altman Z-Score of -5.3 warrants caution. On valuation, the stock is strong 20.7% free cash flow yield. Growth dynamics show revenue growing at 132.5% and profit growth of 8.2%. Our composite FairStock Score of 46/100 reflects mixed fundamentals overall. Without profitability, this remains speculative—suitable only for those with high risk tolerance and a long time horizon.

Bull Case

MacroGenics's 133% revenue growth trajectory could accelerate as it captures additional market share in the healthcare sector. With $12 million in annual free cash flow (5.7% yield), management has ample capital for buybacks, dividends, or accretive acquisitions.

Bear Case

Without a clear path to profitability, continued cash burn forces either dilutive equity raises or debt accumulation that destroys shareholder value. Regulatory changes, input cost inflation, or demand normalization represent underappreciated risks that could materially impact forward estimates.

Data from SEC filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer